Sun Yue, Geng Xiaorui, Wang Yihui, Su Xiaomin, Han Ruyin, Wang Jiangyue, Li Xinyan, Wang Pan, Zhang Kun, Wang Xiaobing
National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, The People's Republic of China.
Shannxi Blood Center, Xi'an 710061, The People's Republic of China.
ACS Pharmacol Transl Sci. 2021 Feb 4;4(2):802-812. doi: 10.1021/acsptsci.1c00004. eCollection 2021 Apr 9.
The clinical applications of many photosensitizers (PSs) are limited because of their poor water solubility, weak tissue penetration, low chemical purity, and severe toxicity in the absence of light. We designed a novel chlorin-based PS (designated as HPS) to achieve fluorescence image-guided photodynamic therapy (PDT) with efficient ROS generation. In addition to its simple fabrication process, HPS has other advantages such as excellent water solubility, strong NIR absorption, and high biocompatibility upon chemical functionalization for enhanced phototherapy. HPS exhibited high photodynamic performance against lung cancer and breast cancer cells by generating a large amount of singlet oxygen (O) under 654 nm laser irradiation. HPS accumulated into multiple organelles such as mitochondria and the endoplasmic reticulum and triggered cell apoptosis by laser exposure. In the tumor-bearing mice, , HPS showed an optimal half-life in circulation and achieved fluorescence-image-guided PDT within the irradiation window, resulting in effective tumor growth inhibition and the prolonged survival of animals. Moreover, the antitumor PDT effect of HPS was close to the clinical trial phase II stage of HPPH even at the low dosage of 0.32 mg/kg (under 75 J/cm laser), while the systemic safety of HPS was much higher. In conclusion, HPS is a novel water-soluble chlorin derivative with excellent PDT potential for clinical transformation.
许多光敏剂(PSs)的临床应用受到限制,因为它们的水溶性差、组织穿透性弱、化学纯度低,且在无光条件下毒性严重。我们设计了一种新型的基于二氢卟吩的光敏剂(命名为HPS),以实现具有高效活性氧生成的荧光图像引导光动力疗法(PDT)。除了其简单的制备过程外,HPS还具有其他优点,如优异的水溶性、强烈的近红外吸收以及在化学功能化后具有高生物相容性以增强光疗效果。在654 nm激光照射下,HPS通过产生大量单线态氧(O)对肺癌和乳腺癌细胞表现出高光动力性能。HPS积聚到线粒体和内质网等多个细胞器中,并通过激光照射触发细胞凋亡。在荷瘤小鼠中,HPS在循环中显示出最佳半衰期,并在照射窗口内实现了荧光图像引导的PDT,从而有效抑制肿瘤生长并延长动物存活时间。此外,即使在0.32 mg/kg的低剂量(75 J/cm激光照射下),HPS的抗肿瘤PDT效果也接近HPPH的临床试验II期阶段,而HPS的全身安全性要高得多。总之,HPS是一种新型的水溶性二氢卟吩衍生物,具有优异的PDT潜力,可用于临床转化。